Lebrikizumab Gets the Nod for Treating Moderate-to-Severe Atopic Dermatitis in Europe

Lebrikizumab, an interleukin-13 inhibitor, is not yet approved in the United States.

Related Keywords

Germany ,United States ,Eli Lilly ,Drug Administration ,European Commission ,New England Journal ,Global Assessment ,Dermatitis ,Europe ,European ,Biologic Therapy ,Atopic Dermatitis ,Topical Corticosteroids ,Corticosteroid ,Interleukins ,Ocular Allergies ,Llergic Eye Diseases ,Llergic Ophthalmologic Conditions ,Corneal Disease ,Allergic Conjunctivitis ,Conjunctivitis ,Adolescent Medicine ,Eczema ,Monoclonal Antibody ,Etuximab ,Ituximab ,Severity Indices ,Topical Therapy ,